ALMS (Alumis) Debt-to-Asset : 0.08 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alumis Debt-to-Asset?

Alumis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.47 Mil. Alumis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $29.63 Mil. Alumis's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $412.56 Mil. Alumis's debt to asset for the quarter that ended in Sep. 2024 was 0.08.

Alumis Debt-to-Asset Historical Data

The historical data trend for Alumis's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Debt-to-Asset Chart

Alumis Annual Data

Trend

Dec22

Dec23

Debt-to-Asset

0.02

0.36

Alumis Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial			-	0.36	0.18	0.12	0.08

Competitive Comparison of Alumis's Debt-to-Asset

For the Biotechnology subindustry, Alumis's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alumis's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alumis's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Alumis's Debt-to-Asset falls into.

Alumis Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Alumis's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.72	+	30.86)	/	89.612
	=	0.36

Alumis's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.467	+	29.631)	/	412.559
	=	0.08

Alumis (NAS:ALMS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Alumis Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Alumis's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alumis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

280 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alumis.com

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.